Phase 3 Lung Cancer Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• You must be an adult (18 years or older, or the minimum legal adult age in your country) at the time you sign the consent form.
• You must have been diagnosed with extensive-stage small cell lung cancer (a type of lung cancer that has spread beyond one lung), confirmed by a lab test on a tissue or cell sample.
• You must have already received one prior treatment that included a platinum-based chemotherapy drug combined with a type of immunotherapy (called a PD-(L)1 inhibitor) for at least 2 rounds, followed by a break of more than 30 days, and your cancer must have continued to grow or spread after that treatment. Previous treatment with a specific drug called tarlatamab is also allowed.
• You must have at least one measurable area of cancer that can be tracked on scans, as assessed by the study doctor.
• You must be able to understand and agree to the study requirements by signing a consent form.
• You must have body organs functioning well enough to participate, and you must be generally well enough to carry out daily activities with no or minimal limitations (as measured by a standard doctor's assessment scale).

Who may not be able to join:

• You may not join if your small cell lung cancer has been identified as a specific rare subtype called "complex SCLC" or "transformed SCLC."
• You may not join if your small cell lung cancer was originally diagnosed as "limited stage" (meaning it had not spread widely at the time of first diagnosis).
• You may not join if you have previously received a type of targeted drug treatment called an antibody-drug conjugate (ADC) containing a TOPO1 inhibitor, or any treatment that targets a protein called B7-H3.
• You may not join if you have a known allergy or sensitivity to any ingredients in the study drug, which in the doctor's opinion would make it unsafe for you to participate.
• You may not join if you have severe, uncontrolled, or currently active heart or blood vessel problems.
• You may not join if you have had significant or uncontrolled bleeding in the month before starting the study.
• You may not join if you have an active infection that needs treatment with medication, or if you are known to have HIV.
• You may not join if you have brain metastases (cancer that has spread to the brain) causing symptoms, untreated brain progression, or cancer that has spread to the lining of the brain, brainstem, or spinal cord.
• You may not join if you currently have or have previously had a serious lung inflammation condition (called interstitial lung disease or pneumonitis) that required high-dose steroid treatment.
• You may not join if you have significant or uncontrolled lung or breathing problems, such as uncontrolled asthma, COPD, or restricted lung function.
• You may not join if you currently have active Hepatitis B or Hepatitis C (liver infections caused by viruses).

Important: Always verify eligibility with the trial site directly before applying.